PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34835933-0	2021	Combination of Trans-Resveratrol and epsilon-Viniferin Induces a Hepatoprotective Effect in Rats with Severe Acute Liver Failure via Reduction of Oxidative Stress and MMP-9 Expression.	epsilon-viniferin	37-54	matrix metallopeptidase 9	Rattus norvegicus	167-172
34835933-4	2021	Resveratrol + epsilon-viniferin significantly decreased TBARS and SOD activity and restored CAT and GST activities in the treated group.	epsilon-viniferin	14-31	catalase	Rattus norvegicus	92-95
34835933-6	2021	The combination of resveratrol + epsilon-viniferin had a hepatoprotective effect, reducing DNA damage, exhibiting a protective role on the antioxidant pathway by altering SOD, CAT, and GST activities; by downregulating TNFalpha, COX-2, and iNOS; and upregulating IL-10.	epsilon-viniferin	33-50	catalase	Rattus norvegicus	176-179
34835933-6	2021	The combination of resveratrol + epsilon-viniferin had a hepatoprotective effect, reducing DNA damage, exhibiting a protective role on the antioxidant pathway by altering SOD, CAT, and GST activities; by downregulating TNFalpha, COX-2, and iNOS; and upregulating IL-10.	epsilon-viniferin	33-50	tumor necrosis factor	Rattus norvegicus	219-227
34835933-6	2021	The combination of resveratrol + epsilon-viniferin had a hepatoprotective effect, reducing DNA damage, exhibiting a protective role on the antioxidant pathway by altering SOD, CAT, and GST activities; by downregulating TNFalpha, COX-2, and iNOS; and upregulating IL-10.	epsilon-viniferin	33-50	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	229-234
34835933-6	2021	The combination of resveratrol + epsilon-viniferin had a hepatoprotective effect, reducing DNA damage, exhibiting a protective role on the antioxidant pathway by altering SOD, CAT, and GST activities; by downregulating TNFalpha, COX-2, and iNOS; and upregulating IL-10.	epsilon-viniferin	33-50	nitric oxide synthase 2	Rattus norvegicus	240-244
34835933-6	2021	The combination of resveratrol + epsilon-viniferin had a hepatoprotective effect, reducing DNA damage, exhibiting a protective role on the antioxidant pathway by altering SOD, CAT, and GST activities; by downregulating TNFalpha, COX-2, and iNOS; and upregulating IL-10.	epsilon-viniferin	33-50	interleukin 10	Rattus norvegicus	263-268
34144024-0	2021	The anti-inflammatory effect of epsilon-viniferin by specifically targeting formyl peptide receptor 1 on human neutrophils.	epsilon-viniferin	32-49	formyl peptide receptor 1	Homo sapiens	76-101
34144024-4	2021	Briefly, epsilon-viniferin specifically inhibited fMLP (0.1 muM: formyl peptide receptor 1 agonist or 1 muM: formyl peptide receptor 1, 2 agonist)-induced superoxide anion production in a concentration-dependent manner (IC50=2.30+-0.96 or 9.80+-0.21 muM, respectively) without affecting this induced by formyl peptide receptor 2 agonist (WKYMVM).	epsilon-viniferin	9-26	formyl peptide receptor 1	Homo sapiens	65-90
34144024-4	2021	Briefly, epsilon-viniferin specifically inhibited fMLP (0.1 muM: formyl peptide receptor 1 agonist or 1 muM: formyl peptide receptor 1, 2 agonist)-induced superoxide anion production in a concentration-dependent manner (IC50=2.30+-0.96 or 9.80+-0.21 muM, respectively) without affecting this induced by formyl peptide receptor 2 agonist (WKYMVM).	epsilon-viniferin	9-26	formyl peptide receptor 1	Homo sapiens	109-134
34144024-5	2021	epsilon-viniferin inhibited fMLP (0.1 muM)-induced phosphorylation of ERK, Akt, Src or intracellular calcium mobilization without affecting these caused by WKYMVM.	epsilon-viniferin	0-17	mitogen-activated protein kinase 1	Homo sapiens	70-73
34144024-5	2021	epsilon-viniferin inhibited fMLP (0.1 muM)-induced phosphorylation of ERK, Akt, Src or intracellular calcium mobilization without affecting these caused by WKYMVM.	epsilon-viniferin	0-17	AKT serine/threonine kinase 1	Homo sapiens	75-78
34144024-5	2021	epsilon-viniferin inhibited fMLP (0.1 muM)-induced phosphorylation of ERK, Akt, Src or intracellular calcium mobilization without affecting these caused by WKYMVM.	epsilon-viniferin	0-17	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	80-83
34144024-9	2021	ATPgammaS induced superoxide anion production through formyl peptide receptor 1 in fMLP desensitized neutrophils and this effect was inhibited by epsilon-viniferin.	epsilon-viniferin	146-163	formyl peptide receptor 1	Homo sapiens	54-79
34144024-12	2021	These results suggest that epsilon-viniferin is an antagonist of formyl peptide receptor 1 in a reversible and non-competitive manner.	epsilon-viniferin	27-44	formyl peptide receptor 1	Homo sapiens	65-90
33140813-0	2020	epsilon-Viniferin, a promising natural oligostilbene, ameliorates hyperglycemia and hyperlipidemia by activating AMPK in vivo.	epsilon-viniferin	0-17	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	113-117
33143552-9	2022	The results of 100 ns MD simulation, RMSF, SASA, Rg, and MM/PBSA show that Epsilon-viniferin (-29.240 kJ/mol), Mpro-Peimisine (-43.031 kJ/mol) and Gmelanone (-13.093 kJ/mol) form a stable complex with Mpro and could be used as potential inhibitors of SARS-CoV-2 Mpro.	epsilon-viniferin	75-92	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	111-115
33143552-9	2022	The results of 100 ns MD simulation, RMSF, SASA, Rg, and MM/PBSA show that Epsilon-viniferin (-29.240 kJ/mol), Mpro-Peimisine (-43.031 kJ/mol) and Gmelanone (-13.093 kJ/mol) form a stable complex with Mpro and could be used as potential inhibitors of SARS-CoV-2 Mpro.	epsilon-viniferin	75-92	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	201-205
33143552-9	2022	The results of 100 ns MD simulation, RMSF, SASA, Rg, and MM/PBSA show that Epsilon-viniferin (-29.240 kJ/mol), Mpro-Peimisine (-43.031 kJ/mol) and Gmelanone (-13.093 kJ/mol) form a stable complex with Mpro and could be used as potential inhibitors of SARS-CoV-2 Mpro.	epsilon-viniferin	75-92	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	201-205
32394973-4	2020	Treatment with epsilon-viniferin upregulated SIRT3 expression, which promoted FOXO3 deacetylation and nuclear localization.	epsilon-viniferin	15-32	sirtuin 3	Homo sapiens	45-50
32394973-4	2020	Treatment with epsilon-viniferin upregulated SIRT3 expression, which promoted FOXO3 deacetylation and nuclear localization.	epsilon-viniferin	15-32	forkhead box O3	Homo sapiens	78-83
32394973-7	2020	However, when cells were transfected with SIRT3 or FOXO3 shRNA prior to rotenone and epsilon-viniferin treatment, these changes were reversed.	epsilon-viniferin	85-102	sirtuin 3	Homo sapiens	42-47
32394973-7	2020	However, when cells were transfected with SIRT3 or FOXO3 shRNA prior to rotenone and epsilon-viniferin treatment, these changes were reversed.	epsilon-viniferin	85-102	forkhead box O3	Homo sapiens	51-56
32394973-8	2020	The results from the present study indicate that epsilon-viniferin enhances SIRT3-mediated FOXO3 deacetylation, reduces oxidative stress, and maintains mitochondrial homeostasis, thus inhibiting rotenone-induced cell apoptosis.	epsilon-viniferin	49-66	sirtuin 3	Homo sapiens	76-81
32394973-8	2020	The results from the present study indicate that epsilon-viniferin enhances SIRT3-mediated FOXO3 deacetylation, reduces oxidative stress, and maintains mitochondrial homeostasis, thus inhibiting rotenone-induced cell apoptosis.	epsilon-viniferin	49-66	forkhead box O3	Homo sapiens	91-96
32512223-14	2020	Topical epsilon-viniferin alleviated psoriasiform symptoms and reduced IL-23 secretion (by 58% vs. 37%) more effectively than resveratrol.	epsilon-viniferin	8-25	interleukin 23, alpha subunit p19	Mus musculus	71-76
32118360-3	2020	Both 5 muM epsilon-viniferin and delta-viniferin, but not 5 muM resveratrol, significantly stimulated wound repair of VECs.	epsilon-viniferin	11-28	latexin	Homo sapiens	7-10
32118360-4	2020	Increased levels of wound repair induced by 10 and 20 muM epsilon-viniferin were significantly higher than those stimulated by 10 and 20 muM resveratrol, respectively.	epsilon-viniferin	58-75	latexin	Homo sapiens	54-57
31646682-5	2020	Among them, trans-epsilon-viniferin showed the most potent cytotoxicity against HL-60 cells (IC50 5.6 muM); ampelopsin E exhibited the most obvious antiproliferative properties on COLO205 (IC50 78.1 muM) and HT-29 (IC50 4.2 muM) cells, and betulinic acid showed the strongest growth inhibitory effects on HepG2 (IC50 6.6 muM) and AGS (IC50 5.4 muM) cells.	epsilon-viniferin	12-35	latexin	Homo sapiens	102-105
31646682-9	2020	Among them, trans-epsilon-viniferin showed the most potent cytotoxicity against HL-60 cells (IC50 5.6 muM); ampelopsin E exhibited the most obvious antiproliferative properties on COLO205 (IC50 78.1 muM) and HT-29 (IC50 4.2 muM) cells, and betulinic acid showed the strongest growth inhibitory effects on HepG2 (IC50 6.6 muM) and AGS (IC50 5.4 muM) cells.	epsilon-viniferin	12-35	latexin	Homo sapiens	102-105
31125704-8	2019	While epsilon-viniferin causes a clear substrate shunt towards the remaining AA cascade enzymes (15-LOX, cyclooxygenase - COX-1/2, cytochrome P450), resveratrol inhibited the COX-1/2 pathway and showed a weak attenuation of 12/15-LOX activity.	epsilon-viniferin	6-23	arachidonate 15-lipoxygenase	Homo sapiens	97-103
31125704-8	2019	While epsilon-viniferin causes a clear substrate shunt towards the remaining AA cascade enzymes (15-LOX, cyclooxygenase - COX-1/2, cytochrome P450), resveratrol inhibited the COX-1/2 pathway and showed a weak attenuation of 12/15-LOX activity.	epsilon-viniferin	6-23	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	122-127
30997467-5	2019	Encapsulation of epsilon-viniferin drastically increased its water solubility by more than 5 orders to reach 17.4 g L-1 and provided protection against its UV-induced isomerization.	epsilon-viniferin	17-34	immunoglobulin kappa variable 1-16	Homo sapiens	116-119
30892883-8	2019	Additionally, VEGF-induced PLCgamma1 phosphorylation was significantly inhibited by epsilon-viniferin, astringin, and omega-viniferin.	epsilon-viniferin	84-101	vascular endothelial growth factor A	Homo sapiens	14-18
30892883-8	2019	Additionally, VEGF-induced PLCgamma1 phosphorylation was significantly inhibited by epsilon-viniferin, astringin, and omega-viniferin.	epsilon-viniferin	84-101	phospholipase C gamma 1	Homo sapiens	27-36
30892883-9	2019	However, epsilon-viniferin and pallidol simultaneously enhanced eNOS activation, proving to be via Akt activation in the case of epsilon-viniferin.	epsilon-viniferin	9-26	nitric oxide synthase 3	Homo sapiens	64-68
30892883-9	2019	However, epsilon-viniferin and pallidol simultaneously enhanced eNOS activation, proving to be via Akt activation in the case of epsilon-viniferin.	epsilon-viniferin	9-26	AKT serine/threonine kinase 1	Homo sapiens	99-102
30892883-9	2019	However, epsilon-viniferin and pallidol simultaneously enhanced eNOS activation, proving to be via Akt activation in the case of epsilon-viniferin.	epsilon-viniferin	129-146	AKT serine/threonine kinase 1	Homo sapiens	99-102
30892883-10	2019	For the first time, these data suggest that stilbenes such as astringin, pallidol, omega-viniferin, and epsilon-viniferin have a potential anti-angiogenic effect and they could be further considered as anti-VEGF ingredients in food and beverages.	epsilon-viniferin	104-121	vascular endothelial growth factor A	Homo sapiens	207-211
30892883-11	2019	In addition, epsilon-viniferin and pallidol significantly allowed eNOS activation and could likely prevent the side effects caused by anti-VEGF hypertension drugs.	epsilon-viniferin	13-30	nitric oxide synthase 3	Homo sapiens	66-70
30892883-11	2019	In addition, epsilon-viniferin and pallidol significantly allowed eNOS activation and could likely prevent the side effects caused by anti-VEGF hypertension drugs.	epsilon-viniferin	13-30	vascular endothelial growth factor A	Homo sapiens	139-143
29476302-14	2018	Caspase-9 was activated at 44.5% after combined treatment for 24 h. This rate is higher than using cis-platin (14.2%) or epsilon-viniferin (43.3%) alone.	epsilon-viniferin	121-138	caspase 9	Homo sapiens	0-9
29155014-0	2018	Resveratrol dimer trans-epsilon-viniferin prevents rotaviral diarrhea in mice by inhibition of the intestinal calcium-activated chloride channel.	epsilon-viniferin	18-41	chloride channel accessory 4B	Mus musculus	110-144
29155014-2	2018	Here, we report the resveratrol dimer trans-epsilon-viniferin (TV) and tetramer r-2-viniferin (RV) as inhibitors of the intestinal calcium-activated chloride channel (CaCC) and demonstrate their antisecretory efficacy in a neonatal mouse model of rotaviral diarrhea.	epsilon-viniferin	38-61	chloride channel accessory 4B	Mus musculus	131-165
29155014-2	2018	Here, we report the resveratrol dimer trans-epsilon-viniferin (TV) and tetramer r-2-viniferin (RV) as inhibitors of the intestinal calcium-activated chloride channel (CaCC) and demonstrate their antisecretory efficacy in a neonatal mouse model of rotaviral diarrhea.	epsilon-viniferin	38-61	chloride channel accessory 4B	Mus musculus	167-171
29155014-2	2018	Here, we report the resveratrol dimer trans-epsilon-viniferin (TV) and tetramer r-2-viniferin (RV) as inhibitors of the intestinal calcium-activated chloride channel (CaCC) and demonstrate their antisecretory efficacy in a neonatal mouse model of rotaviral diarrhea.	epsilon-viniferin	63-65	chloride channel accessory 4B	Mus musculus	131-165
29155014-2	2018	Here, we report the resveratrol dimer trans-epsilon-viniferin (TV) and tetramer r-2-viniferin (RV) as inhibitors of the intestinal calcium-activated chloride channel (CaCC) and demonstrate their antisecretory efficacy in a neonatal mouse model of rotaviral diarrhea.	epsilon-viniferin	63-65	chloride channel accessory 4B	Mus musculus	167-171
29155014-4	2018	TV primarily inhibited the physiologically relevant, long-term CaCC current following agonist stimulation, without effect on cytoplasmic Ca2+ signaling.	epsilon-viniferin	0-2	chloride channel accessory 4B	Mus musculus	63-67
27162263-8	2016	Moreover, the mucosal epsilon-viniferin concentration-dependently attenuated the mucosal propionate (1 mmol/L)-evoked increases in Isc and Gt Immunohistochemical studies revealed COX-1-immunoreactive epithelial cells in the cecal crypt.	epsilon-viniferin	22-39	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	179-184
23570675-13	2013	As the glucose transport/uptake was decreased after preincubation with either trans-resveratrol or epsilon-viniferin this active transport mechanism was directly influenced by inhibiting the SGLT1 transport system.	epsilon-viniferin	99-116	solute carrier family 5 (sodium/glucose cotransporter), member 1	Mus musculus	191-196
22762395-6	2012	The isolated compounds, including (+)-vitisin A, ampelopsin C, and (+)-epsilon-viniferin, were shown to have anti-ACE and vasodilating effects against phenylephrine-induced tensions in an endothelium-intact aortic ring, with (+)-vitisin A being the most effective compound.	epsilon-viniferin	67-88	angiotensin I converting enzyme	Rattus norvegicus	114-117
21524590-0	2011	Protective effect of epsilon-viniferin on beta-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry.	epsilon-viniferin	21-38	amyloid beta precursor protein	Homo sapiens	42-62
18001803-4	2007	Whereas cells treated with resveratrol accumulate in S phase, cells treated with epsilon-viniferin and miyabenol C accumulate in G2/M and G0/G1, respectively.	epsilon-viniferin	81-98	proline rich protein BstNI subfamily 3	Homo sapiens	132-143
16472225-9	2005	The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of epsilon-viniferin for the PDE4 subtype.	epsilon-viniferin	94-111	aldehyde dehydrogenase 7 family member A1	Homo sapiens	52-55
16472225-9	2005	The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of epsilon-viniferin for the PDE4 subtype.	epsilon-viniferin	94-111	phosphodiesterase 4A	Homo sapiens	120-124
12818727-0	2003	Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages.	epsilon-viniferin	60-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
12818727-2	2003	As resveratrol and polyphenols from red wine were reported to inhibit cytochrome P450 (CYP) activities, this led us to investigate the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.	epsilon-viniferin	157-174	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	184-190
12818727-2	2003	As resveratrol and polyphenols from red wine were reported to inhibit cytochrome P450 (CYP) activities, this led us to investigate the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.	epsilon-viniferin	157-174	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	192-198
12818727-6	2003	epsilon-viniferin displayed a more potent inhibitory effect than resveratrol for all the CYP activities tested (Ki 0.5 to 20 microM vs. 10 to 100 microM, respectively).	epsilon-viniferin	0-17	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-92
12818727-11	2003	Comparison of the inhibitory effects exerted on CYP activities by epsilon-viniferin, resveratrol and non volatile components from red wine or various Cognac beverages showed that neither resveratrol, nor epsilon-viniferin is the main CYP inhibitor present in red wine solids.	epsilon-viniferin	66-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
34728247-5	2021	alpha-Viniferin induced apoptosis in HOS cells by decreasing expression of phospho-c-Jun-N-terminal kinase 1/2 (p-JNK1/2) and increasing expression of cleaved Poly (ADP-ribose) polymerase (PARP), whereas alpha-viniferin in combination with epsilon-viniferin induced apoptosis in A549 cells by decreasing expression of phospho-protein kinase B (p-AKT) and increasing expression of cleaved PARP and cleaved caspase-3.	epsilon-viniferin	240-257	mitogen-activated protein kinase 8	Homo sapiens	114-120
34728247-5	2021	alpha-Viniferin induced apoptosis in HOS cells by decreasing expression of phospho-c-Jun-N-terminal kinase 1/2 (p-JNK1/2) and increasing expression of cleaved Poly (ADP-ribose) polymerase (PARP), whereas alpha-viniferin in combination with epsilon-viniferin induced apoptosis in A549 cells by decreasing expression of phospho-protein kinase B (p-AKT) and increasing expression of cleaved PARP and cleaved caspase-3.	epsilon-viniferin	240-257	poly(ADP-ribose) polymerase 1	Homo sapiens	159-187
34728247-5	2021	alpha-Viniferin induced apoptosis in HOS cells by decreasing expression of phospho-c-Jun-N-terminal kinase 1/2 (p-JNK1/2) and increasing expression of cleaved Poly (ADP-ribose) polymerase (PARP), whereas alpha-viniferin in combination with epsilon-viniferin induced apoptosis in A549 cells by decreasing expression of phospho-protein kinase B (p-AKT) and increasing expression of cleaved PARP and cleaved caspase-3.	epsilon-viniferin	240-257	AKT serine/threonine kinase 1	Homo sapiens	346-349
34728247-5	2021	alpha-Viniferin induced apoptosis in HOS cells by decreasing expression of phospho-c-Jun-N-terminal kinase 1/2 (p-JNK1/2) and increasing expression of cleaved Poly (ADP-ribose) polymerase (PARP), whereas alpha-viniferin in combination with epsilon-viniferin induced apoptosis in A549 cells by decreasing expression of phospho-protein kinase B (p-AKT) and increasing expression of cleaved PARP and cleaved caspase-3.	epsilon-viniferin	240-257	poly(ADP-ribose) polymerase 1	Homo sapiens	388-392
34728247-5	2021	alpha-Viniferin induced apoptosis in HOS cells by decreasing expression of phospho-c-Jun-N-terminal kinase 1/2 (p-JNK1/2) and increasing expression of cleaved Poly (ADP-ribose) polymerase (PARP), whereas alpha-viniferin in combination with epsilon-viniferin induced apoptosis in A549 cells by decreasing expression of phospho-protein kinase B (p-AKT) and increasing expression of cleaved PARP and cleaved caspase-3.	epsilon-viniferin	240-257	caspase 3	Homo sapiens	405-414